Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma.

Yeung C, Gibson AE, Issaq SH, Oshima N, Baumgart JT, Edessa LD, Rai G, Urban DJ, Johnson MS, Benavides GA, Squadrito GL, Yohe ME, Lei H, Eldridge S, Hamre J 3rd, Dowdy T, Ruiz-Rodado V, Lita A, Mendoza A, Shern JF, Larion M, Helman LJ, Stott GM, Krishna MC, Hall MD, Darley-Usmar V, Neckers LM, Heske CM.

Cancer Res. 2019 Oct 1;79(19):5060-5073. doi: 10.1158/0008-5472.CAN-19-0217. Epub 2019 Aug 20.

PMID:
31431459
2.

Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma.

Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ.

Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12.

3.

Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of AAV Serotypes 4, 5, and 11.

Earley LF, Powers JM, Adachi K, Baumgart JT, Meyer NL, Xie Q, Chapman MS, Nakai H.

J Virol. 2017 Jan 18;91(3). pii: e01980-16. doi: 10.1128/JVI.01980-16. Print 2017 Feb 1.

4.

The Role of PDGFR-β Activation in Acquired Resistance to IGF-1R Blockade in Preclinical Models of Rhabdomyosarcoma.

Heske CM, Yeung C, Mendoza A, Baumgart JT, Edessa LD, Wan X, Helman LJ.

Transl Oncol. 2016 Dec;9(6):540-547. doi: 10.1016/j.tranon.2016.09.002. Epub 2016 Nov 16.

5.

STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.

Heske CM, Mendoza A, Edessa LD, Baumgart JT, Lee S, Trepel J, Proia DA, Neckers L, Helman LJ.

Oncotarget. 2016 Oct 4;7(40):65540-65552. doi: 10.18632/oncotarget.11869.

Supplemental Content

Loading ...
Support Center